Charmaine Roson - Philippines

“As more ASEAN countries harmonize with the CSDT format, the easier it will be for manufacturers to leverage existing documentation in new markets.”

Charmaine Roson
Principal Consultant
Asia Actual Philippines

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

Sign Up For Our Newsletter to Stay Informed

Sign Up

Philippines FDA to Expedite Applications Approved Under AMDD-CSDT

Published on: January 24th, 2022

Another Reason for Manufacturers to Develop their CSDT Documentation

The Food and Drug Administration (FDA) of the Philippines released FDA Advisory 2021-3084 on November 18, 2021, providing an abridged review route for products registered by an ASEAN member’s regulatory authority under the AMDD-CSDT requirements. The Advisory comes as CMDR review times increase and more ASEAN members implement harmonized standards such as the Common Submission Dossier Template (CSDT) application format. Manufacturers will still need to submit complete CSDT documentation pursuant to Administrative Order No. 2018-0002 entitled “Guidelines Governing the Issuance of an Authorization for a Medical Device Based on the ASEAN Harmonized Technical Requirements” but can expect quicker market access.

At this time, approvals using CSDT documentation from the following competent authorities will receive an expedited review:

The route applies to Class B, C, and D products and products approved through abridged routes in. Manufacturers will need to submit a declaration of conformity stating that the submitted CSDT documents are the exact same used for the approval in the ASEAN member state being leveraged. At this time Class B, C, and D CMDRs are requiring 4-8 months for the Philippines FDA to review.

AMDD-CSDT Documentation Requirements

The ASEAN Common Submission Dossier Template (CSDT) was developed by the ASEAN Member States (AMS) to harmonize medical device applications across all member states to ease the regulatory burden for manufacturers. CSDT documentation includes:

  1. Executive Summary
    1. Device Description
    2. Intended use
    3. Indications
    4. Instruction for use
    5. Storage condition
    6. Shelf life
    7. Contradictions
    8. Warnings
    9. Precautions
    10. Potential adverse Effects
    11. Alternative Therapy
    12. Materials
    13. Other Relevant specifications
    14. Other descriptive Information
  2. Device Labelling
  3. Detailed Manufacturer Information
  4. Essential Principles of Safety and Performance of Medical Device and Method Used to demonstrate conformity
  5. Summary of Design verification and validation documents
  6. Risk Analysis
  7. Method of destruction
  8. Quality Management Certification
  9. Letter of Certification of the intended use/indication/ Package, Letter of certification of label and instruction for use from manufacturer or product owners
  10. Declaration of Conformity
  11. Letter of Confirmation for market history proof from manufacturer
  12. Letter of Safety confirmation from manufacturer
  13. Proof of approval from Medical Device Regulatory Authority in Foreign Countries
  14. Letter of Authorization as Distributor for Manufacturer
  15. Grouping indication letter

Grow With Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market. Contact Asia Actual today to see how new regulatory developments may affect your business in the Philippines.

Blog Posts

India Grants Import License Grace Period for Class A/B Devices

Released on September 30, 2022, the Central Drugs Standard Control Organisation (CDSCO) issued Circular File No. 29/Misc/03/2022-DC (257) providing an Import License grace period to all Non-Regulatory Class A and B medical devices.
Class A Exempt Instruments

India Issues Draft Notification for Exempting Certain Class A Medical Devices

The Indian Ministry of Health and Family Welfare (Department of Health and Family Welfare) issued the draft Notification G.S.R. 710(E) on 20 September, 2022 that, if formalized, would exempt Class A non-measuring and non-sterile medical devices.

Transfer of Product Registration of Alcohol Swabs from CDRRHR to CDRR

Announced on September 6, 2022, FDA Advisory 2022-1576, the Philippines FDA has announced that the alcohol swabs with at least 70% isopropyl alcohol intended for antiseptic use now falls under the jurisdiction of the Center for Drug Regulation Research (CDRR) under Household Remedy Products.